VEGF and their inhibiting antibodies and drugs already have a high relevance in clinical practice, as it is used as a therapeutical drug for tumor treatment (Fernando and Hurwitz, 2004; Hutson et al., 2013), or in diabetic retinopathy (Das et al., 2015), age-related macular degeneration (Solomon et al., 2014) and intracranial injuries (Talwar and Srivastava, 2014). The gene discussed is VEGFA; the disease is diabetic retinopathy.